Yazar "Okur H." seçeneğine göre listele

Listeleniyor 1 - 3 / 3
  • [ X ]
    Öğe
    Differential expression of CD34, S100, and c-Kit in interstitial cells of Cajal in infantile hypertrophic pyloric stenosis - Immunochemical study
    (2009) Ozturk H.; Ozturk H.; Yilmaz F.; Okur H.; Otcu S.; Dokucu A.I.
    Background. The pathogenesis of infantile hypertrophic pyloric stenosis (IHPS) is poorly understood although many hypotheses have been proposed. Objectives. Assessment whether the differential expression of c-Kit, CD34, and S100 may be involved in the development of IHPS. Material and Methods. Specimens from 14 infants with IHPS and seven control subjects were immunohisto-chemically stained for c-Kit, CD34, and S 100. The numbers of CD34+, S 100+, and c-Kit+ cells in five random fields per specimen were compared via light microscopy (x200). Results. In normal pyloric tissue, specific and intense c-Kit immunoreactivity was observed in the muscle layers and moderate staining was observed around the myenteric plexus. In IHPS patients, c-Kit+ cells were either absent or markedly reduced around the myenteric plexus. In control and IHPS patients, CD34+ cells were not observed around the myenteric plexus. In the vascular endothelium, moderate CD34 staining was observed in specimens from control subjects, whereas intense staining was observed for IHPS patients. In normal pyloric tissue, moderate S 100 immunoreactivity was observed in the muscle layers and intense staining was observed in the myenteric plexus. In IHPS patients, few S100+ cells were observed in the pyloric muscle layers and S100 immunoreactivity decreased markedly around the myenteric plexus. Conclusions. These results suggest that the numbers of c-Kit+ and S100+ cells are markedly decreased in the pyloric muscle layers and around the myenteric plexus in IHPS patients. Thus a lack of c-Kit and S100, but not CD34, expression may be a critical factor in the pathogenesis of IHPS and may serve as a useful prognostic tool in the treatment of this disease. © Copyright by Wroclaw Medical University.
  • [ X ]
    Öğe
    Follow-up and therapeutic approach in children with sacrococcygeal teratoma
    (2007) Çiğdem M.K.; Önen A.; Otçu S.; Okur H.; Akay H.
    Sacrococcygeal teratoma (SCT) is the most common solid tumor in neonates. In this study, we retrospectively reviewed 32 SCT patients who were treated and followed in our clinic between 1983 and 2006. Of all the patients, 13 were bigger than 12 months of age. Only 11 patients were present during the neonatal period. The presenting symptoms were sacral mass in 27 patients, difficulty voiding in 3, and difficult defecation in 2 patients. Pathological examination revealed mature teratoma in 17 patients, yolk sac tumor in 9, and immature teratoma in 6 patients. Of the patients who were diagnosed after 1 month of age, 43 % were found to have malignant tumor. Recurrence was observed in five patients during follow-up period; 4 were yolk sac and one was immature teratoma. Postoperative recurrence time was between 6 and 36 months. Two patients died intraoperatively due to massive bleeding, while the other four died due to metastases after chemotherapy. Early (antenatal) diagnosis, early and complete surgical resection of tumor with coccyx is important in reducing morbidity and mortality. Postoperative follow-up might include sacral examination and blood AFP level for at least 3 years in terms of tumor recurrence.
  • [ X ]
    Öğe
    Which treatment in retrocaval ureter in children?
    (2007) Çiğdem M.K.; Önen A.; Okur H.; Akay H.
    Retrocaval ureter is a rare condition in pediatric population. In this study, we present the diagnosis, therapeutic approach and follow-up of our two cases with retrocaval ureter. One of these underwent surgical correction due to persistent severe hydronephrosis and significant symptoms. We treated the second patient conservatively because, of moderate hydronephrosis and normal renal function with no symptoms. The treatment approach in patients associated with retrocaval ureter might be similar to these patients with UPJ-type hydronephrosis.